This is a randomized, placebo controlled, double blind study in healthy subjects and subjects with atopic dermatitis that is designed to assess the safety and tolerability of FRTX-02 capsules at single and multiple ascending doses.~Safety will be assessed through vital signs, ECG, adverse events and safety laboratory tests.~Pharmacokinetic and pharmacodynamic information will also be collected.
FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.